Clinical Trials

1 studies in Membranous Nephropathy

1. Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Rochester, MN View Summary
   Close

   Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The purpose of this study is to provide the clinician with placebo-controlled safety and efficacy data for the indicated use of Acthar in the treatment of idiopathic membranous nephropathy. Questcor has chosen to evaluate Acthar in those who are treatment-resistant with a low probability of spontaneous remission. The dose regimens selected are designed to be within the FDA approved package insert, and to provide clinically-actionable data consistent with the clinical practice of dose titration.

   NCT ID:

   NCT01386554

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   - Mayo Clinic Cancer Center - Phone: 507-538-7623 - Research Volunteer Program - Phone: 1-800-664-4542 (toll-free) Email: clinicaltrials@mayo.edu - International Research - Phone: 507-284-8884 Email: intl.mcr@mayo.edu